Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.23)
# 1,048
Out of 4,711 analysts
191
Total ratings
44.76%
Success rate
2.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Upgrades: Overweight | $45 → $67 | $46.24 | +44.90% | 10 | Dec 13, 2024 | |
| FOLD Amicus Therapeutics | Downgrades: Equal-Weight | $17 → $12 | $9.80 | +22.45% | 4 | Dec 13, 2024 | |
| BIOA BioAge Labs | Initiates: Overweight | $40 | $6.14 | +551.47% | 1 | Oct 21, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Overweight | $92 → $95 | $83.45 | +13.84% | 5 | Oct 11, 2024 | |
| CNTA Centessa Pharmaceuticals | Upgrades: Overweight | $11 → $26 | $17.16 | +51.52% | 1 | Sep 19, 2024 | |
| ENGN enGene Holdings | Maintains: Overweight | $40 | $5.83 | +586.11% | 2 | Sep 11, 2024 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Equal-Weight | $28 → $20 | $16.87 | +18.55% | 23 | Aug 7, 2024 | |
| CRVO CervoMed | Initiates: Overweight | $35 | $2.23 | +1,469.51% | 1 | Jul 26, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Equal-Weight | $160 → $150 | $122.97 | +21.98% | 4 | Jul 12, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $160 → $170 | $135.42 | +25.54% | 24 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $53.60 | +30.60% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $13.50 | +85.19% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $40 | $64.50 | -37.98% | 5 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $28.67 | +91.84% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $60 → $90 | $48.87 | +84.16% | 12 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $1.30 | +207.69% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $1.70 | +135.29% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $55 | $56.12 | -2.00% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.44 | +801.10% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $60 → $140 | $8.50 | +1,547.06% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $84 | $44.22 | +89.96% | 7 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $40 | $14.68 | +172.48% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $2.00 | +600.00% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $1.96 | +155.10% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $2.19 | +36.99% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.32 | +960.61% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $19 | $11.60 | +63.79% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 | $2.54 | +490.55% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $2.33 | +329.18% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $33.29 | -33.91% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $36.26 | +309.54% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $3.05 | +1,867.21% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $5.75 | +4.35% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $54 | $0.97 | +5,467.01% | 6 | May 8, 2020 |
PTC Therapeutics
Dec 13, 2024
Upgrades: Overweight
Price Target: $45 → $67
Current: $46.24
Upside: +44.90%
Amicus Therapeutics
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $17 → $12
Current: $9.80
Upside: +22.45%
BioAge Labs
Oct 21, 2024
Initiates: Overweight
Price Target: $40
Current: $6.14
Upside: +551.47%
Intra-Cellular Therapies
Oct 11, 2024
Maintains: Overweight
Price Target: $92 → $95
Current: $83.45
Upside: +13.84%
Centessa Pharmaceuticals
Sep 19, 2024
Upgrades: Overweight
Price Target: $11 → $26
Current: $17.16
Upside: +51.52%
enGene Holdings
Sep 11, 2024
Maintains: Overweight
Price Target: $40
Current: $5.83
Upside: +586.11%
ACADIA Pharmaceuticals
Aug 7, 2024
Downgrades: Equal-Weight
Price Target: $28 → $20
Current: $16.87
Upside: +18.55%
CervoMed
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $2.23
Upside: +1,469.51%
Jazz Pharmaceuticals
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $160 → $150
Current: $122.97
Upside: +21.98%
Neurocrine Biosciences
Jul 12, 2024
Maintains: Overweight
Price Target: $160 → $170
Current: $135.42
Upside: +25.54%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $53.60
Upside: +30.60%
Apr 30, 2024
Initiates: Overweight
Price Target: $25
Current: $13.50
Upside: +85.19%
Apr 2, 2024
Maintains: Equal-Weight
Price Target: $75 → $40
Current: $64.50
Upside: -37.98%
Feb 20, 2024
Initiates: Overweight
Price Target: $55
Current: $28.67
Upside: +91.84%
Jan 5, 2024
Downgrades: Equal-Weight
Price Target: $60 → $90
Current: $48.87
Upside: +84.16%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $1.30
Upside: +207.69%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $1.70
Upside: +135.29%
Dec 19, 2023
Upgrades: Overweight
Price Target: $29 → $55
Current: $56.12
Upside: -2.00%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.44
Upside: +801.10%
Dec 8, 2023
Upgrades: Equal-Weight
Price Target: $60 → $140
Current: $8.50
Upside: +1,547.06%
Nov 3, 2023
Maintains: Overweight
Price Target: $90 → $84
Current: $44.22
Upside: +89.96%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $14.68
Upside: +172.48%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $2.00
Upside: +600.00%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $1.96
Upside: +155.10%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.19
Upside: +36.99%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.32
Upside: +960.61%
Feb 3, 2023
Maintains: Overweight
Price Target: $27 → $19
Current: $11.60
Upside: +63.79%
Feb 3, 2023
Upgrades: Overweight
Price Target: $15
Current: $2.54
Upside: +490.55%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $2.33
Upside: +329.18%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $33.29
Upside: -33.91%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $36.26
Upside: +309.54%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $3.05
Upside: +1,867.21%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $5.75
Upside: +4.35%
May 8, 2020
Maintains: Overweight
Price Target: $58 → $54
Current: $0.97
Upside: +5,467.01%